Swedbank
ALXN

Swedbank’s Alexion Pharmaceuticals ALXN Stock Holding History

Swedbank’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,355,389
Closed -$249M – 769
2021
Q2 		$249M Sell
1,355,389
-35,889
-3% -$6.16M 0.47% 42
2021
Q1 		$213M Sell
1,391,278
-746,983
-35% -$116M 0.44% 46
2020
Q4 		$334M Sell
2,138,261
-479,333
-18% -$61.6M 0.98% 27
2020
Q3 		$300M Sell
2,617,594
-13,687
-0.5% -$1.48M 1.03% 23
2020
Q2 		$295M Sell
2,631,281
-818,520
-24% -$86.9M 1.07% 24
2020
Q1 		$310M Buy
3,449,801
+256,871
+8% +$25.2M 1.53% 17
2019
Q4 		$343M Buy
3,192,930
+539,356
+20% +$57.7M 1.39% 15
2019
Q3 		$260M Buy
2,653,574
+1,224,177
+86% +$138M 1.18% 23
2019
Q2 		$187M Buy
1,429,397
+698,096
+95% +$90M 0.85% 38
2019
Q1 		$98.9M Sell
731,301
-130,044
-15% -$16.2M 0.47% 78
2018
Q4 		$83.7M Buy
861,345
+273,800
+47% +$32.4M 0.46% 76
2018
Q3 		$81.7M Sell
587,545
-233,345
-28% -$29.3M 0.37% 84
2018
Q2 		$102M Buy
+820,890
New +$95.9M 0.5% 70

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Swedbank's ALXN Position: Q3 2021 in Review

Swedbank sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,355,389 shares — an estimated $249M sold.

Swedbank first reported a position in ALXN in Q2 2018 and held it in 13 quarters. The position peaked at $343M in Q4 2019. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Swedbank reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Swedbank sold 1,355,389 Alexion Pharmaceuticals shares in Q3 2021, an estimated $249M.
  • Swedbank first reported a position in Alexion Pharmaceuticals in Q2 2018 and held it in 13 quarters.
  • Swedbank's Alexion Pharmaceuticals position peaked at $343M in Q4 2019.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Swedbank's 13F filing for Q3 2021, filed 6 Dec 2024.